1. Home
  2. AQST vs VIR Comparison

AQST vs VIR Comparison

Compare AQST & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aquestive Therapeutics Inc.

AQST

Aquestive Therapeutics Inc.

HOLD

Current Price

$3.92

Market Cap

707.6M

Sector

Health Care

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$5.85

Market Cap

825.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQST
VIR
Founded
2004
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
707.6M
825.0M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
AQST
VIR
Price
$3.92
$5.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
11
Target Price
$8.83
$25.73
AVG Volume (30 Days)
4.3M
1.7M
Earning Date
11-05-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,397,000.00
$16,860,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$52.34
$46.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.12
$4.16
52 Week High
$7.55
$13.74

Technical Indicators

Market Signals
Indicator
AQST
VIR
Relative Strength Index (RSI) 22.22 45.56
Support Level $5.86 $5.55
Resistance Level $6.59 $6.30
Average True Range (ATR) 0.32 0.30
MACD -0.13 -0.02
Stochastic Oscillator 11.98 39.60

Price Performance

Historical Comparison
AQST
VIR

About AQST Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Share on Social Networks: